The Better Way Back(R), a NuVasive(R) Patient Education Program, Reaches 1,000 Patient Ambassadors

The Better Way Back(R), a NuVasive(R) Patient Education Program, Reaches 1,000 
Patient Ambassadors 
SAN DIEGO, CA -- (Marketwire) -- 02/05/13 --    NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
is pleased to announce that The Better Way Back(R), a NuVasive
supported patient education program, has reached over 1,000 active
patient ambassadors nationwide.  
The Better Way Back's ambassadors are patients who have undergone
spine surgery and who volunteer time to share their stories with
pre-operative patients who are medically indicated and contemplating
spine surgery. Most Better Way Back patient ambassadors are XLIF(R)
(eXtreme Lateral Interbody Fusion) recipients. 
"Reaching 1,000 patient ambassadors is a significant milestone in
patient spine care," said Rolf Benirschke, senior partner of Legacy
Health Strategies, a patient engagement company that manages The
Better Way Back Program. "We have ambassadors in every state who
educate and support patients suffering from chronic back and leg pain
-- this has offered many patients hope for the future." 
Established in 2010, The Better Way Back has been steadfast in its
commitment to raising public awareness of spine disorders by
educating patients, loved ones, clinicians, and healthcare providers
about spine surgery treatment options. By speaking with a patient
ambassador who has suffered from a similar condition or selected the
same surgeon, patients and their loved ones can receive a balanced
perspective on spine treatment options.  
"I'm finally able to do some good and give back after my own positive
experience with spine surgery," said Kathleen Mosko, a patient
ambassador for The Better Way Back. "As an ambassador, I can tell
patients that they are not alone and that I understand their pain and
concerns. I have spoken with hundreds of patients over the past
couple of years and I'm proud to be doing what I do. I know it makes
a real difference in the lives of others." 
In addition to sharing stories with pre-operative patients, patient
ambassadors routinely speak out on behalf of patients who may be too
consumed with pain to speak for themselves. By raising awareness with
legislative and regulatory decision makers, The Better Way Back
community continues to make a nationwide impact by leading the charge
to educate patients about spine disorders, innovative treatment
options, and positive patient outcomes.  
For more information about The Better Way Back or to speak to a
Patient Ambassador, please visit, or call
About NuVasive 
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $8.2
billion global spine market. NuVasive's principal product offering is
based on its Maximum Access Surgery, or MAS(R) platform. The MAS
platform combines several categories of solutions that collectively
minimize soft tissue disruption during spine surgery with maximum
visualization and safe, easy reproducibility for the surgeon: a
proprietary software-driven nerve avoidance system and
intra-operative monitoring support; MaXcess(R), a unique split-blade
retractor system; a wide variety of specialized implants; and several
biologic fusion enhancers. MAS significantly reduces surgery time and
returns patients to activities of daily living much faster than
conventional approaches. Having redefined spine surgery with the MAS
platform's lateral approach, known as eXtreme Lateral Interbody
Fusion, or XLIF(R), NuVasive has built an entire spine franchise.
With over 80 products today spanning lumbar, thoracic and cervical
applications, the Company will continue to expand and evolve its
offering predicated on its R&D focus and dedication to outstanding
service levels supported by a culture of Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
risk that NuVasive's revenue or earnings projections may turn out to
be inaccurate because of the preliminary nature of the forecasts and
the risk of further adjustment, or unanticipated difficulty in
selling products or generating expected profitability; the uncertain
process of seeking regulatory approval or clearance for NuVasive's
products or devices, including risks that such process could be
significantly delayed; the possibility that the FDA may require
significant changes to NuVasive's products or clinical studies; the
risk that products may not perform as intended and may therefore not
achieve commercial success; the risk that competitors may develop
superior products or may have a greater market position enabling more
successful commercialization; the risk that additional clinical data
may call into question the benefits of NuVasive's products to
patients, hospitals and surgeons; and other risks and uncertainties
more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission. NuVasive's
public filings with the Securities and Exchange Commission are
available at NuVasive assumes no obligation to update
any forward-looking statement to reflect events or circumstances
arising after the date on which it was made. 
Stephan Ogilvie 
VP, Corporate Development & Investor Relations 
Nicholas S. Laudico
The Ruth Group
Press spacebar to pause and continue. Press esc to stop.